Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 7276 to 7290 of 7702 results

  1. Antimicrobial prescribing: Ceftazidime/avibactam (ES16)

    This evidence summary has been updated and replaced by NICE antimicrobial health technology evaluation guidance on ceftazidime with avibactam for treating severe drug-resistant gram-negative bacterial infections.  

    Evidence summary
    Published
    13 November 2017

  2. Preventing recurrence of Clostridium difficile infection: bezlotoxumab (ES13)

    This advice has been updated and replaced by NICE guideline NG199.

    Evidence summary
    Published
    6 June 2017

  3. Nivolumab for adjuvant treatment of resected non-small-cell lung cancer [ID4053]

    In development [GID-TA10935] Expected publication date: TBC

    Technology appraisal guidance
    In development

  4. Sepsis (QS161)

    February 2024: We have temporarily withdrawn this quality standard due to ongoing updates to the NICE guideline on sepsis, which underpins the quality statements. See the guidance in development page and guideline in development page for progress on these updates.

    For any queries, please contact qualitystandards@nice.org.uk

    Quality standard
    Last updated
    18 June 2020

  5. Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]

    In development [GID-TA10800] Expected publication date: TBC

    Technology appraisal guidance
    In development

  6. High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis

    Discontinued [GID-IPG10142]

    Interventional procedures guidance
    Discontinued

  7. COVID-19 rapid guideline: severe asthma (NG166)

    May 2022: This guideline has been withdrawn because current practice is to manage COVID-19 risk in line with risk of other respiratory infections. See our guidance on treating severe asthma and our guideline on managing COVID-19.

    COVID-19 rapid guideline
    Published
    3 April 2020

  8. Palforzia for treating peanut allergy in children aged 1 to 3 [ID6144]

    In development [GID-TA11070] Expected publication date: TBC

    Technology appraisal guidance
    In development

  9. Ruxolitinib for treating moderate to severe chronic graft-versus-host disease after an allogeneic stem cell transplant in people 28 days to 17 years [ID6427]

    In development [GID-TA11523] Expected publication date: TBC

    Technology appraisal guidance
    In development

  10. Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica

    Discontinued [GID-IP2806]

    Interventional procedures guidance
    Discontinued

  11. MRI guided focussed ultrasound for chronic pain

    Discontinued [GID-IP1043]

    Interventional procedures guidance
    Discontinued

  12. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development [GID-IPG10394] Expected publication date: TBC

    Interventional procedures guidance
    In development

  13. Atezolizumab for untreated advanced or recurrent non-small cell lung cancer when platinum-doublet chemotherapy is unsuitable [ID6218]

    In development [GID-TA11139] Expected publication date: TBC

    Technology appraisal guidance
    In development

  14. Lung transplantation with ex-vivo perfusion

    Discontinued [GID-IP1046]

    Interventional procedures guidance
    Discontinued

  15. GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)

    Discontinued [GID-MT557]

    Medical technologies guidance
    Discontinued